TNO is a biomedical institute developing platforms which accelerate and de-risk drug development. We have developed in vitro and ex vivo platforms enabling the investigation of oral absorption, gut metabolism, inflammatory responses, hepatic/renal clearance and DDIs.
Besides we can measure microbiome mediated drug metabolism. TNO has access to accelerated mass spectrometry systems (AMS). Via
AMS studies the whole ADME package (PK, AbsBA, MIST and mass balance) can be generated in early clinical development.
Our DMPK/ADME capabilities support drug delivery and drug formulation development.